Project Grant R44AI157900
Award Date
5/1/21
Completion Date
6/30/23
Dollars Obligated
$3.8M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Synbal, Inc. (PZKSBR7YKLF4)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institutes of Health's (NIH) Research Infrastructure Programs (CFDA 93.351) provides $775,888 to the La Jolla Institute for Immunology to develop and validate a novel CRISPR-ready, HLA transgenic mouse platform. The platform will enable researchers to rapidly generate mice expressing specific HLA class I and II alleles relevant to a broad range of diseases, including infection, cancer, autoimmunity, and transplant rejection. This versatile platform will...
This Project Grant award from the National Institutes of Health (NIH), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,035,691 to Wake Forest University Health Sciences (WFUHS) to develop novel mouse models of hepatitis B virus (HBV) infection and replication. The goal is to create robust mouse models to investigate HBV infection, transcription, replication, pathogenesis, and host immune response, as well as to evaluate HBV-specific antiviral drugs and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the impact of immune imprinting on SARS-CoV-2 variant vaccination strategies using a humanized mouse model. The total funding amount is $193,644.00, with an award date of August 15, 2024, and an ultimate completion date of July 31, 2029. The research seeks to understand how prior exposure to the SARS-CoV-2...
This Project Grant award, valued at $582,618.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to determine the mechanisms by which RNA N6-methyladenosine (m6A) and pseudouridine (Ψ) modifications modulate SARS-CoV-2 replication, gene expression, immunity, and pathogenesis. The project involves using CRISPR-Cas9 to knock out host RNA m6A methyltransferases...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $844,954 to New York University School of Medicine to develop "Genomically Rewritten and Tailored Humanized Mouse Models for Various Organ Disorders". The award leverages advanced DNA synthesis and genome editing technologies to create mouse models that accurately recapitulate human disease phenotypes. These "GREAT-GEMMS" (Genomically...
This federal Project Grant award of $705,557, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Emory University to advance the understanding of mucosal immunity and T cell responses against SARS-CoV-2 infection. The primary objectives are to: 1) Determine the role of inflammatory monocytes in promoting protective T cell responses in the upper and lower respiratory tract...
This $862,440 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to evaluate novel gene editing therapies targeting chronic hepatitis B virus (HBV) infection using a new humanized mouse model. The key objectives are to: 1) Assess the anti-HBV efficacy of different gene editing nuclease therapies delivered via adeno-associated virus (AAV) and lipid nanoparticles (LNPs) in the NSG-PIZ...
This $240,000 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to develop a novel Golden Syrian hamster model to study the neurological and behavioral impacts on offspring from mothers infected with SARS-CoV-2. The primary objectives are to: 1) Examine the direct effects of maternal SARS-CoV-2 infection on the female...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $870,800 to the University of Maryland, Baltimore to develop an integrated system utilizing fission yeast and human cells to identify human suppressive cellular proteins and small molecule inhibitors that specifically target the SARS-CoV-2 ORF3A protein. The overarching objective is to counteract the cytopathic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $915,178 to the University of Texas Medical Branch at Galveston (UTMB) to develop and evaluate novel hamster models of chikungunya viral arthritis. The researchers will utilize CRISPR/Cas9 gene editing to create hamsters deficient in the STAT2 and IL28RA signaling pathways, which are critical for the host immune...